Biosimilars, Compounding and Immunization

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

JUNE 20, 2025

Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.

Vaccines

Vaccines Pharmacy Technician Immunity Immunization

Top Performing Drug – Enbrel (June Edition)

PharmaShots

JUNE 28, 2023

Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. This list is not an exhaustive list.

Correct Patient Misconceptions Around Biosimilars

Pharmacy Times

JUNE 27, 2025

Misconceptions about biosimilars include doubts about their safety, efficacy, and risks associated with switching from reference biologics. Biosimilars extend beyond cost savings, improving access to essential treatments, especially in underserved populations.

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Pharmacy Times

JUNE 12, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

FDA Approves Ustekinumab-Stba, Biosimilar to Stelara, for Pediatric Patients With PsO or PsA

Pharmacy Times

JUNE 16, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

JULY 4, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

JUNE 20, 2025

They have a team of highly skilled distribution professionals who can juggle efficacy and safety checks along with compounding as if they were conductors of a world-class symphony. We need people to coordinate and track prior authorizations, write persuasive appeal letters, and keep patients updated.

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Top Performing Drug – Enbrel (June Edition)

Trending Sources

Correct Patient Misconceptions Around Biosimilars

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

FDA Approves Ustekinumab-Stba, Biosimilar to Stelara, for Pediatric Patients With PsO or PsA

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Study Shows High-Dose Vitamin D Boosts Treatment Response in Breast Cancer

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

OTC Assessments With Recommendations and Counseling Should Be a Billable Encounter

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Lorundrostat Shows Clinically Meaningful Outcomes in Patients With CKD and Hypertension

Walgreens Launches Program to Enable Technicians to Pursue Pharmacy School

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Study Confirms Interchangeability of Hulio, Biosimilar of Humira, in Severe Chronic Plaque Psoriasis

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

FDA Approves Twice-Yearly Lenacapavir for HIV Preexposure Prophylaxis

Research Suggests Vitamin D Deficiency Is a Risk Factor for Autism

Spring 2025 Quiz: Test Your Pharmacy Knowledge!

OTC Case Studies: Summer Skin Care

Nitisinone Becomes First and Only FDA-Approved Treatment for HGA in Adults With AKU

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

USP announces new Advanced Technologies Laboratory to accelerate and scale pharmaceutical manufacturing innovations

Ropeginterferon Alfa 2b Is Well-Tolerated, Efficacious in Treatment of Prefibrotic Myelofibrosis

ADA 2025: Insights into Diabetes, Obesity, and Pharmacist's Role in Advancing Care

Pharmacies Need Strategies to Improve Health Care Access

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Expanding Access: Digital Therapeutics and the Evolving Role of Pharmacists

Inside the Synergy Between HOPA and OPC’s Evolving Educational Impact

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

ADA 2025: CagriSema Demonstrates Significant Weight Loss in REDEFINE Clinical Trials

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Specialty Pharmacist Integration in Neurology Clinics: A Model for Enhanced Patient Care

INCB057643 in Combination with Ruxolitinib Improves Symptoms in Patients With Myelofibrosis

FDA Approves First, Only Single-Pill Triple Combination for Treatment of Hypertension

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

ADA 2025: Ready-to-Use Glucagon Empowers Diabetes Patient Safety

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Stay Connected